A combination of β-hydroxybutyrate and citrate ameliorates disease progression in a rat model of polycystic kidney disease
A combination of β-hydroxybutyrate and citrate ameliorates disease progression in a rat model of polycystic kidney disease is a paper indexed in ScholarIQ from OpenAlex.
How many citations does A combination of β-hydroxybutyrate and citrate ameliorates disease progression in a rat model of polycystic kidney disease have?
A combination of β-hydroxybutyrate and citrate ameliorates disease progression in a rat model of polycystic kidney disease has 16 citations in the OpenAlex counts ScholarIQ stores.
When was A combination of β-hydroxybutyrate and citrate ameliorates disease progression in a rat model of polycystic kidney disease published?
A combination of β-hydroxybutyrate and citrate ameliorates disease progression in a rat model of polycystic kidney disease has 2023 year in the ScholarIQ index.
What is the open-access status of A combination of β-hydroxybutyrate and citrate ameliorates disease progression in a rat model of polycystic kidney disease?
A combination of β-hydroxybutyrate and citrate ameliorates disease progression in a rat model of polycystic kidney disease has green oa status in the ScholarIQ index.
What is the DOI of A combination of β-hydroxybutyrate and citrate ameliorates disease progression in a rat model of polycystic kidney disease?
The DOI for A combination of β-hydroxybutyrate and citrate ameliorates disease progression in a rat model of polycystic kidney disease is on the source record.
What is the PMID of A combination of β-hydroxybutyrate and citrate ameliorates disease progression in a rat model of polycystic kidney disease?
The PMID for A combination of β-hydroxybutyrate and citrate ameliorates disease progression in a rat model of polycystic kidney disease is on the source record.
What is the OpenAlex record for A combination of β-hydroxybutyrate and citrate ameliorates disease progression in a rat model of polycystic kidney disease?
The OpenAlex for A combination of β-hydroxybutyrate and citrate ameliorates disease progression in a rat model of polycystic kidney disease is on the source record.